The failure of exogenous IFN-γ therapy for RRMS may also be directly related to the general limitations of systemic cytokine monotherapy such as lack of cell targeting and induction of “off target” effects as well as the inability to establish the appropriate cellular crosstalk that is likely to play an important role in reshaping immune responses. This evidence concerns the gene IFNG and relapsing-remitting multiple sclerosis.